24 March 2017 — Global science and technology solutions and services leader Leidos has welcomed¬†√úberResearch to OnPAR, the Online Partnership to Accelerate Research. OnPAR, originally launched by the Leidos Life Sciences team in March 2016, is a partnership with the National Institutes of Health (NIH). It offers a new funding paradigm with the goal of matching highly scored, unfunded grant applications with potential non-government funding organizations. √úberResearch contributes key capabilities from its Dimensions platform to provide pertinent global funding landscape data and its unique natural language processing (NLP) matching tool that routes relevant grant applications to funders.
“√úberResearch provides critical information for funding organizations, and it is a natural partner for OnPAR,” says Martin Due√Īas, Director, Health Research Management Practice, Leidos Life Sciences.
√úberResearch’s Dimensions is a decision support system that analyzes strategic research investments by funders, universities, and other stakeholders throughout the research ecosystem. The platform provides insight into the international funding landscape, covering over $1 trillion in awards from millions of research projects funded by hundreds of government, non-profit, and private funding organizations. Dimensions offers a single platform to examine research funding and outputs alike using the very best decision support tools available.
“We are thrilled to partner with Leidos in support of the OnPAR effort. Dimensions will provide additional information including a broad view of the global research landscape to facilitate more informed research investment decisions,” says Dr. Duane Williams, Vice President of √úberResearch.
OnPAR with Dimensions will provide a global research knowledge management platform that will empower funding organizations and private industry to make more informed strategic investments. In addition, the data mining tools and analytics within OnPAR with Dimensions will facilitate greater perspective, and insight previously unavailable, by linking research projects and literature that were never before recognized as relevant, ultimately furthering advances in research discovery and development.
OnPAR is increasing its enrollment and will announce new members in spring 2017, including additional foundations, pharmaceutical companies, and other life sciences funding organizations across varied disease areas.
Any funding organization interested in becoming a member can find more information on the OnPAR website at https://onpar.leidosweb.com. Leidos welcomes both new partners and members to participate in this effort. Please visit OnPAR frequently for further announcements and join the team to accelerate research and find cures and treatments for the many diseases affecting our communities.
√úberResearch, a member of the Digital Science family with Altmetric, Figshare, Readcube, and Symplectic,¬†focuses on building Portfolio Analysis, Reviewer Identification, Categorization, and Search and Discovery systems for Research Funders. The √úberResearch team has worked for over 15 years producing solutions that apply analytical technology like NLP to science content including publications, grants, patents, clinical trials, and more. Clients range from the largest funding agencies and most prestigious scientific publishers to the smallest foundations and non-profits. For more information, visit uberresearch.com.
Leidos is a global science and technology solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company’s Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.